Sandbox: ATL: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 3: Line 3:


===prognosis===
===prognosis===
Clinical form
 
age
 
poor clinical performance status
high lactate dehydrogenase (LDH)  
high lactate dehydrogenase (LDH)  
high β2‐microglobulin
high β2‐microglobulin
high leukemic counts
 
hypercalcemia
high serum level of CD25
high serum level of CD25
high serum neuron‐specific enolase
high serum neuron‐specific enolase
Line 22: Line 20:
|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Age'''|| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Clinical form'''|| style="padding: 5px 5px; background: #F5F5F5;" |
:* Older age at the time of diagnosis is associated with a worse prognosis.
:* Older age at the time of diagnosis is associated with a worse prognosis.


|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Gender'''|| style="padding: 5px 5px; background: #F5F5F5;"|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Age'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:* Males are associated with a worse prognosis when compared to females.
:* Males are associated with a worse prognosis when compared to females.
|-
|-
Line 36: Line 34:
|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Stage'''|| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Calcium level'''|| style="padding: 5px 5px; background: #F5F5F5;" |
:*Binet stages B and C or Rai stages 2-4 are associated with a worse prognosis.
:*Binet stages B and C or Rai stages 2-4 are associated with a worse prognosis.


|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lymphocyte doubling time'''|| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Leukocyte count'''|| style="padding: 5px 5px; background: #F5F5F5;" |
:*A rapid [[lymphocyte]] doubling time is associated with a worse prognosis.
:*A rapid [[lymphocyte]] doubling time is associated with a worse prognosis.


|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Genetic mutations'''|| style="padding: 5px 5px; background: #F5F5F5;"|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lactate dehydrogenase level'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:*Deletion of [[chromosome 17]] short arm and [[chromosome 11]] long arm are associated with a worse prognosis.
:*Deletion of [[chromosome 17]] short arm and [[chromosome 11]] long arm are associated with a worse prognosis.


|-
|-


|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Prolymphocytes percent'''|| style="padding: 5px 5px; background: #F5F5F5;" |
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''β2-microglobulin level'''|| style="padding: 5px 5px; background: #F5F5F5;" |
:*An increased percentage of [[prolymphocyte]]s is associated with a worse prongnosis.
:*An increased percentage of [[prolymphocyte]]s is associated with a worse prongnosis.


Line 72: Line 70:


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lymphocyte surface markers'''|| style="padding: 5px 5px; background: #F5F5F5;"|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lymphocyte surface markers'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:*Over expression of [[CD38]] is associated with a worse prognosis.
:*Over expression of [[CD25]] is associated with a worse prognosis.
|-
|-


| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Immunoglobulin (Ig)VH gene'''|| style="padding: 5px 5px; background: #F5F5F5;"|
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Neuron‐specific enolase'''|| style="padding: 5px 5px; background: #F5F5F5;"|
:*The absence of IgVH [[gene]] mutation is associated with a worse prognosis.
:*The absence of IgVH [[gene]] mutation is associated with a worse prognosis.



Revision as of 19:56, 24 January 2016

[1][2][3]


prognosis

high lactate dehydrogenase (LDH) high β2‐microglobulin

high serum level of CD25 high serum neuron‐specific enolase

Prognostic Factor Description
Clinical form
  • Older age at the time of diagnosis is associated with a worse prognosis.
Age
  • Males are associated with a worse prognosis when compared to females.
Performance status
Calcium level
  • Binet stages B and C or Rai stages 2-4 are associated with a worse prognosis.
Leukocyte count
  • A rapid lymphocyte doubling time is associated with a worse prognosis.
Lactate dehydrogenase level
β2-microglobulin level
  • An increased percentage of prolymphocytes is associated with a worse prongnosis.
Histological analysis
Lactate dehydrogenase (LDH) level
  • Elevated level of LDH is associated with a worse prognosis.
β2-microglobulin level
  • Elevated level of β2-microglobulin level is associated with a worse prognosis.
Lymphocyte surface markers
  • Over expression of CD25 is associated with a worse prognosis.
Neuron‐specific enolase
  • The absence of IgVH gene mutation is associated with a worse prognosis.
Membrane-bound proteins
  • The expression of zeta-chain-associated protein kinase 70 (ZAP) is associated with a worse prognosis.
  1. Mahieux R, Gessain A (2007). "Adult T-cell leukemia/lymphoma and HTLV-1". Curr Hematol Malig Rep. 2 (4): 257–64. doi:10.1007/s11899-007-0035-x. PMID 20425378.
  2. Matutes E (2007). "Adult T-cell leukaemia/lymphoma". J Clin Pathol. 60 (12): 1373–7. doi:10.1136/jcp.2007.052456. PMC 2095573. PMID 18042693.
  3. Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y; et al. (2015). "Treatment and survival among 1594 patients with ATL". Blood. 126 (24): 2570–7. doi:10.1182/blood-2015-03-632489. PMID 26361794.